<upn class="cxwwn"></upn>

NO钱包(中国)

Be the most trusted biotech company

2025-09-24

Results of Serplulimab in Lung and Gastrointestinal Cancer Selected for ESMO 2025: Late-Breaking Abstract and Oral Presentations
2025-09-24

First Patient Dosed in Argentina for the Phase 3 Head-to-Head Trial of HLX22 in Gastric Cancer
2025-09-22

Henlius Participates in FDA Biosimilars Industry Roundtable
2025-09-19

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-09-19

First Patient Dosed in Australia for a Phase 2 International Clinical Trial of Henlius' PD-L1 ADC HLX43 for NSCLC
2025-09-17

Henlius Achieves Breakthrough in First-Line Breast Cancer Therapy: Innovative CDK4/6 Inhibitor FUTUONING Approved for New Indication
2025-09-15

WCLC 2025 Henlius’ Deep Dive, Broad Impact: Global Lung Cancer Dialogue Reception Successfully Concluded
2025-09-12

A New First-Line Option for EGFR Overexpression Patients: Henlius Presents Updated Phase 2 Data of HLX07 Combination Therapy in sqNSCLC
2025-09-09

U.S. FDA Clearance of IND for Pembrolizumab Biosimilar HLX17

1
2
3
4
5
6
7
...
14